Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer.

ChIP-seq showed there was a highly significant correlation ( p values < 10 −16 ) between ER binding fold changes induced by the addition of elacestrant or fulvestrant in the three cell lines tested (Pearson correlations with p values <10 −16 ; 0.78 MCF7, 0.47 MCF7-LTED wt and 0.60 MCF7-LTED Y537C ) especially in regions where there was increased ER binding after treatment versus E2 (Fig. 4A ).

also in 132,142 other papers